Merck & Co. Inc. buy Finanzgonzo
Start price
28.07.11
/
50%
€24.30
Target price
09.01.12
€30.00
Performance (%)
26.55%
End price
09.01.12
€30.16
Summary
This prediction ended on 09.01.12 with a price of €30.16. The BUY prediction by Finanzgonzo finished with a performance of 26.55%. Finanzgonzo has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Merck & Co. Inc. | 2.529% | 2.529% | 20.872% | 1.152% |
| iShares Core DAX® | 0.024% | 0.583% | 11.674% | 61.622% |
| iShares Nasdaq 100 | 1.740% | -2.061% | 4.180% | 88.706% |
| iShares Nikkei 225® | 0.428% | 10.487% | 29.994% | 67.054% |
| iShares S&P 500 | 1.329% | 0.140% | 3.333% | 60.858% |
Comments by Finanzgonzo for this prediction
In the thread Merck & Co. Inc. diskutieren
zulassung für victrelis in europa
Merck & Co hat die Zulassung für das Hepatitis C - Medikament Victrelis von der Europäischen Kommission erhalten. Kooperation mit Roche.
Quelle: Der Aktionär Nr. 31 / 2011
(Vom Mitglied beendet)